Clinical Trials
3 trialsNCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00023621 2013-06-26
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025051 2013-03-22
Celecoxib in Preventing Skin Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn